Eduardo Hösel Miranda

Eduardo Hösel Miranda

Auto-generated profile, based on publicly available information

Eduardo Hösel Miranda

Pharmaceutical Nanotechnology Laboratory. Universidade Estadual do Centro-Oeste. Alameda Élio Antonio Dalla Vecchia, 838 - CEP 85040-167, Guarapuava-PR. Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2021 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
DRDaniele Fernanda Renzi
Daniele Fernanda Renzi
LCLaís de Almeida Campos
Laís de Almeida Campos
EMEduardo Hösel Miranda
Eduardo Hösel Miranda
Rubiana Mara MainardesRubiana Mara Mainardes
Rubiana Mara Mainardes
Wolf-Rainer AbrahamWolf-Rainer Abraham
Wolf-Rainer Abraham
NKNajeh Maissar Khalil
Najeh Maissar Khalil
Fungal infections are diseases that are considered neglected although their infection rates have increased worldwide in the last decades. Thus, since the antifungal arsenal is restricted and many strains have shown resistance, new therapeutic alternatives are necessary. Nanoparticles are considered important alternatives to promote drug delivery. In this sense, the objective of the present study was to evaluate the contributions of newly developed nanoparticles to the treatment of fungal infections. Studies have shown that nanoparticles generally improve the biopharmaceutical and pharmacokinetic characteristics of antifungals, which is reflected in a greater pharmacodynamic potential and lower toxicity, as well as the possibility of prolonged action. It also offers the proposition of new routes of administration. Nanotechnology is known to contribute to a new drug delivery system, not only for the control of infectious diseases but for various other diseases as well. In recent years, several studies have emphasized its application in infectious diseases, presenting better alternatives for the treatment of fungal infections.